Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

Sesen Bio Receives NASDAQ Delisting Notice

Business Wire January 30, 2023

Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders

Business Wire January 26, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MAXR, SESN, IMRA, ELVT

PR Newswire January 25, 2023

Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support

Business Wire January 25, 2023

SHAREHOLDER ALERT: Weiss Law Reminds DCT, PAYA, DCP, and SESN Shareholders About Its Ongoing Investigations

PR Newswire January 24, 2023

Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics

Business Wire January 19, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SESN, MLVF, GMGI

PR Newswire January 18, 2023

SHAREHOLDER ALERT: Weiss Law Reminds DCP, SESN, MLVF, and VLON Shareholders About Its Ongoing Investigations

PR Newswire January 17, 2023

SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing Investigations

PR Newswire January 6, 2023

Investor Group Issues Letter to Sesen Bio's Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger

Business Wire January 5, 2023

Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics

Business Wire January 4, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, HZNP, SESN

PR Newswire January 3, 2023

Investor Group Reiterates Intent to Vote AGAINST Sesen Bio's Value-Destructive Merger with Carisma

Business Wire January 3, 2023

SHAREHOLDER ALERT: Weiss Law Reminds WEBR, SESN, MLVF, and VLON Shareholders About Its Ongoing Investigations

PR Newswire December 29, 2022

Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger

Business Wire December 29, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, SESN, LBAI, FORG

PR Newswire December 21, 2022

SHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and MTCR Shareholders About Its Ongoing Investigations

PR Newswire December 20, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MVBF, EQ, MTCR, SESN

PR Newswire December 14, 2022

SHAREHOLDER ALERT: Weiss Law Investigates Sesen Bio, Inc.

PR Newswire December 13, 2022

Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update

Business Wire November 7, 2022